[1] Wynn TA. Cellular and molecular mechanisms of fibrosis [J].J Pathology, 2008, 214(2):199-210.
[2] Wigginton JE, Kischner D.A model to predict cell-mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis [J].J Immunol, 2001,166(3):1951-1967.
[3] Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, Tsai MM, Flynn JL, Chan J. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology[J]. Infect Immune,2001,69(3):1847-1855.
[4] Casarini M, Ameglio F, Alemanno L, Zangrilli P, Mattia P, Paone G, Bisetti A, Giosuè S. Cytokine levels correlate with a radiological score in active pulmonary tuberculosis[J].Am J Respir Crit Care Med,1999,159(1):143-148.
[5] Turgut T, Akbulut H. Serum interleukin-2 and neopterin levels as useful markers for treatment of active pulmonary tuberculosis [J]. Tohoku J Exp Med, 2006,209(4):321-328.
[6] Ameglio F, Casarini M, Capoluongo P. Mattia,G. Puglisi S. Giosue. Post-treatment changes of six cytokines in active pulmonary tuberculosis: differences between patients with stable or increased fibrosis [J].International Journal of Tubercle and Lung Disease, 2005,9(1):98-104.
[7] Wallace WA, Fitch PM, Simpson AJ, Howie SE. Inflammation-associated remodeling and fibrosis in the lung-a process and an end point [J]. Int J Exp Pathol, 2007,88(2):103-110.
[8] Keane MP, Strieter RM, Belperio JA. Mechanisms and mediators of pulmonary fibrosis [J]. Crit Rev Immunol,2005,25(6):429-463.
|